Company intelligence / Profile preview

Chengdu Mafuisan Pharmaceutical Technology

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Mafuisan Pharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company specializes in targeting G protein-coupled receptors (GPCRs) involved in glucose homeostasis and weight management, such as GLP-1, GCG, and GIP receptors. Their research aims to provide oral alternatives to existing injectable peptide therapies for conditions like Type 2 diabetes and obesity. Mafuisan leverages its expertise in medicinal chemistry and structural biology to optimize drug candidates for improved efficacy and safety profiles.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Chengdu Mafuisan Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Mafuisan Pharmaceutical Technology.

Explore the full profile